Once-daily oral icotrokinra produced sustained plaque psoriasis control through week 112, including scalp, genital, ...
Phase 3 ABTECT-Maintenance will report 44-week efficacy and safety of obefazimod in moderately to severely active UC using a randomized, double-blind, placebo-controlled design. Subset analyses will ...
Yassky, MD, PhD, explains how biomarkers could match patients with inflammatory skin diseases to the right therapy. Emma ...
Icotrokinra (Icotyde) produced skin clearance through 2 years in patients with plaque psoriasis affecting the scalp, genitals, hands, and feet, with 70% achieving clear or almost ...
IL-31 receptor targeting may differentiate nemolizumab by impacting pruritus-driven neuroimmune signaling while also modulating inflammation and epidermal barrier disruption. Correlative analyses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results